Lexicon Pharmaceutical announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses. Pursuant to the terms of the purchase agreement, Lexicon will sell approximately 2.3 million shares of series a convertible preferred stock, at a price per share of $108.50, convertible into approximately 115.2 million shares of its common stock, par value $0.001, to a select group of accredited investors pursuant to the terms of the purchase agreement. Jefferies, Leerink Partners and Piper Sandler acted as placement agents.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LXRX:
- Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
- Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Lexicon management to meet with Piper Sandler